ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib

Cancer Science

Volumn 97, Issue 12, 2006, Pages 1404-1409

  Yang, Yang ^a,b   Ikezoe, Takayuki ^b   Nishioka, Chie ^b   Taguchi, Takahiro ^b   Zhu, Wei Guo ^a   Koeffler, H Phillip ^c   Taguchi, Hirokuni ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b KOCHI UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STEM CELL FACTOR; SUNITINIB; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEINS; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 33750332521     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00325.x     Document Type: Article

References (34)

1. De Giorgi U, Verweij J. Imatinib and gastrointestinal stromal tumors: Where do we go from here? Mol Cancer Ther 2005; 4: 495-501.
2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-69.
3. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55: 1-96.
4. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
5. Corless CL, Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160: 1567-72.
6. Kelly LM, Yu JC, Boulton CL et al. CT53518, a novel selective Flt3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421-32.
7. Skorski T, Kanakaraj P, Nieborowska-Skorska M et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-36.
8. Bjornsti MA, Houghton PJ. Lost in translation: Dysregulation of cap-dependent translation and cancer. Cancer Cell 2004; 5: 519-23.
9. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
10. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by ERK: Implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121: 179-93.
11. Rolfe M, McLeod LE, Pratt PF, Proud CG. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J 2005; 388: 973-84.
12. Taguchi T, Sonobe H, Toyonaga S et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Laboratory Invest 2002; 82: 663-5.
13. Ikezoe T, Yang Y, Nishioka C et al. Effect of SU11248 on GIST-T1 cells: enhancement of growth inhibition via inhibition of PI3-K/Akt/mTOR signaling. Cancer Sci 2006; 97: 945-51.
14. Hennequin LF, Stokes ES, Thomas AP et al. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002; 45: 1300-12.
15. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-56.
16. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62: 7284-90.
17. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-55.
18. Yang Y, Ikezoe T, Takeuchi T et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 2005; 96: 425-33.
19. Yang Y, Takeuchi S, Tsukasaki K et al. Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res 2005; 29: 47-51.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
21. Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small-cell lung cancer. Ann Oncol 2006; 17 (Suppl 2): 46-8.
22. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized Phase II trial. J Clin Oncol 2005; 23: 3697-705.
23. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial -E4599. Proc Am Soc Clin Oncol 2005; LBA4.
24. Miller KD, Wang M, Gralow J et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Proc Am Soc Clin Oncol 2005; LBA23.
25. Rich JN, Sathornsumetee S, Keir ST et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005; 11: 8145-57.
26. Natale RB, Bodkin D, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC. Final results from a two-part, double-blind, randomized phase II trial. Proc Am Soc Clin Oncol 2006; A7000.
27. Heymach JV, Johnson BE, Prager D et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc Am Soc Clin Oncol 2006; A7016.
28. Ikezoe T, Nishioka C, Tasaka T et al. The anti-tumor effects of sunitinib (formerly SU11248) against a variety of human hematological malignancies: Enhancement of growth inhibition via inhibition of mTOR signaling. (ASH Annual Meeting Abstracts) Blood 2005; 106: 2795.
29. Mohi MG, Boulton C, Gu TL et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004; 101: 3130-5.
30. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716-22.
31. van Oosterom AT, Judson IR, Verweij J et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 (Suppl 5): S83-7.
32. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
33. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-11.
34. Carter TA, Wodicka LM, Shah NP et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11 0 11 -6.